Tecelra®, the first engineered T-cell therapy for solid tumors, has received approval from the Food and Drug Administration (FDA) for advanced MAGE-A4+ synovial sarcoma in
Clinical trial results show that pembrolizumab, an immunotherapy drug used to treat multiple types of cancer, can dramatically improve outcomes for patients with colorectal cancer
In the early days of the human immunodeficiency virus (HIV) epidemic, there was little hope. HIV infection, when untreated, damages the immune system, making people
In a pioneering first-in-human clinical trial, an mRNA cancer vaccine developed at the University of Florida (UF) has shown promise in treating patients with primary
Around 200,000 people die from glioblastoma, the most common and most aggressive type of cancerous brain tumor, each year. With a five-year overall survival rate
Recent revelations by celebrities about their cancer diagnoses have cast a spotlight on a worrisome trend: the rise in early-onset cancer rates, or the incidence
In 2024, roughly 2 million people in the United States will be diagnosed with cancer, per the National Cancer Institute. Given that stark statistic, oncology
Artificial intelligence (AI) is rapidly transforming the field of oncology, enhancing the precision of cancer diagnostics and accelerating drug development processes. AI and machine learning
The future of oncology holds immense promise, thanks to the tireless efforts of medical researchers. From innovative oncology drugs like antibody-drug conjugates to advancements in
Death rates for cancer are lower than ever, having declined as much as 33 percent since 1991. This is largely thanks to innovations in oncology
The relationship between cancer and the nervous system has been a curiosity and mystery for nearly two centuries. Jean Cruveilhier’s initial observations in the early
Humans have practiced oncology — the study and treatment of cancer — since long before the invention of the scalpel. The history of oncology drug
Tecelra®, the first engineered T-cell therapy for solid tumors, has received approval from the Food and Drug Administration (FDA) for advanced MAGE-A4+ synovial sarcoma in
Clinical trial results show that pembrolizumab, an immunotherapy drug used to treat multiple types of cancer, can dramatically improve outcomes for patients with colorectal cancer
In the early days of the human immunodeficiency virus (HIV) epidemic, there was little hope. HIV infection, when untreated, damages the immune system, making people
In a pioneering first-in-human clinical trial, an mRNA cancer vaccine developed at the University of Florida (UF) has shown promise in treating patients with primary
Around 200,000 people die from glioblastoma, the most common and most aggressive type of cancerous brain tumor, each year. With a five-year overall survival rate
Recent revelations by celebrities about their cancer diagnoses have cast a spotlight on a worrisome trend: the rise in early-onset cancer rates, or the incidence
In 2024, roughly 2 million people in the United States will be diagnosed with cancer, per the National Cancer Institute. Given that stark statistic, oncology
Artificial intelligence (AI) is rapidly transforming the field of oncology, enhancing the precision of cancer diagnostics and accelerating drug development processes. AI and machine learning
The future of oncology holds immense promise, thanks to the tireless efforts of medical researchers. From innovative oncology drugs like antibody-drug conjugates to advancements in
Death rates for cancer are lower than ever, having declined as much as 33 percent since 1991. This is largely thanks to innovations in oncology
The relationship between cancer and the nervous system has been a curiosity and mystery for nearly two centuries. Jean Cruveilhier’s initial observations in the early
Humans have practiced oncology — the study and treatment of cancer — since long before the invention of the scalpel. The history of oncology drug
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields
Emails are serviced by Constant Contact. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.